Raymond James Financial
TSHA icon

Raymond James Financial’s Taysha Gene Therapies TSHA Stock Holding History

Raymond James Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.5K Buy
22,031
+3,887
+21% +$18.1K ﹤0.01% 5034
2025
Q4 		$99.8K Buy
+18,144
New +$88.1K ﹤0.01% 4925
2025
Q3 		– Sell
-3,605
Closed -$8.33K – 6647
2025
Q2 		$8.33K Buy
+3,605
New +$7.83K ﹤0.01% 5994

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's TSHA Position: Q1 2026 in Review

Raymond James Financial increased its Taysha Gene Therapies (TSHA) stake by 21% in Q1 2026, buying an estimated $18.1K and bringing the position to 22,031 shares worth $98.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5034.

Raymond James Financial first reported a position in TSHA in Q2 2025 and has held it in 3 quarters since. The position peaked at $99.8K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Raymond James Financial held 22,031 shares of Taysha Gene Therapies worth $98.5K as of Q1 2026.
  • Raymond James Financial bought 3,887 Taysha Gene Therapies shares in Q1 2026, an estimated $18.1K.
  • Taysha Gene Therapies made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5034 holding.
  • Raymond James Financial first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Taysha Gene Therapies position peaked at $99.8K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.